Biospectal Selected as Top 3 Innovation Award Finalist for Swiss Medtech Day on June 14, 2022
We are working relentlessly to democratize blood pressure management at global scale using breakthrough transdermal optical biosensing in mobile devices. It’s a privilege to be recognized for our vision, passion, and progress as one of the top three Swiss Medtech Award 2022 Finalists. The winner of the prestigious award and cash prize will be announced
Biospectal Wins Coveted Health Innovator Selection @ SXSW 2022
SXSW 2022 has selected Biospectal to join its list of Innovation Award finalists from a huge number of entries for the award ceremony in Austin, TX on 14 March. Come talk with us about our fingertip optical sensing with OptiBP and Biodisc on Saturday at the Innovator’s showcase!
Biospectal to Debut Biodisc™ and Launch OptiBP for iOS Public Beta at CES 2022
All-in-one blood pressure monitoring device, Biodisc democratizes access and expands the reach of Biospectal’s blood pressure monitoring platform from smartphones and other connected mobile devices, to clinics, hospitals, work and home The Biospectal team is excited to announce the debut of Biodisc™, a stand-alone, sleekly-designed, all-in-one, blood pressure monitoring device at CES 2022. Biospectal also
Biospectal OptiBP Named Winner in Fast Company’s First-Ever List of the Next Big Things in Tech
LAUSANNE, SWITZERLAND – NOVEMBER 18, 2021 – Biospectal SA, the remote patient monitoring biosensing software company, today announced the Biospectal OptiBP™ smartphone blood pressure monitoring app and data platform has been named a winner in the Health category for Fast Company’s Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape
Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink
Today we are happy to announce the closing of a CHF 4.0M($4.3M) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data
Biospectal Announces Two Independent Global Health Research and Validation Studies
We’re proud to announce two independent global research and validation studies which integrate the Biospectal OptiBP™ blood pressure measurement app. Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal’s OptiBP smartphone app